Cover Image
Market Research Report

Alpha Galactosidase A - Pipeline Review, H2 2019

Published by Global Markets Direct Product code 359840
Published Content info 84 Pages
Delivery time: 1-2 business days
Price
Back to Top
Alpha Galactosidase A - Pipeline Review, H2 2019
Published: December 27, 2019 Content info: 84 Pages
Description

Summary

Alpha Galactosidase A (Alpha D-Galactosidase A or Alpha D Galactoside Galactohydrolase or Melibiase or Agalsidase or GLA or EC 3.2.1.22) pipeline Target constitutes close to 13 molecules. Out of which approximately 12 molecules are developed by companies and remaining by the universities/institutes. The latest report Alpha Galactosidase A - Pipeline Review, H2 2019, outlays comprehensive information on the Alpha Galactosidase A (Alpha D-Galactosidase A or Alpha D Galactoside Galactohydrolase or Melibiase or Agalsidase or GLA or EC 3.2.1.22) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.

Alpha Galactosidase A (Alpha D-Galactosidase A or Alpha D Galactoside Galactohydrolase or Melibiase or Agalsidase or GLA or EC 3.2.1.22) - Alpha-galactosidase is a glycoside hydrolase enzyme encoded by the GLA gene. This enzyme is a homodimeric glycoprotein that hydrolyses the terminal alpha-galactosyl moieties from glycolipids and glycoproteins. It predominantly hydrolyzes ceramide trihexoside, and it can catalyze the hydrolysis of melibiose into galactose and glucose. Mutations in this gene affect the synthesis and stability of this enzyme which causes Fabry's disease. The molecules developed by companies in Pre-Registration, Phase III, Phase II and Preclinical stages are 1, 1, 4 and 6 respectively. Similarly, the universities portfolio in Unknown stages comprises 1 molecules, respectively. Report covers products from therapy areas Genetic Disorders which include indications Fabry Disease.

Furthermore, this report also reviews key players involved in Alpha Galactosidase A (Alpha D-Galactosidase A or Alpha D Galactoside Galactohydrolase or Melibiase or Agalsidase or GLA or EC 3.2.1.22) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Scope

  • The report provides a snapshot of the global therapeutic landscape for Alpha Galactosidase A (Alpha D-Galactosidase A or Alpha D Galactoside Galactohydrolase or Melibiase or Agalsidase or GLA or EC 3.2.1.22)
  • The report reviews Alpha Galactosidase A (Alpha D-Galactosidase A or Alpha D Galactoside Galactohydrolase or Melibiase or Agalsidase or GLA or EC 3.2.1.22) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in Alpha Galactosidase A (Alpha D-Galactosidase A or Alpha D Galactoside Galactohydrolase or Melibiase or Agalsidase or GLA or EC 3.2.1.22) targeted therapeutics and enlists all their major and minor projects
  • The report assesses Alpha Galactosidase A (Alpha D-Galactosidase A or Alpha D Galactoside Galactohydrolase or Melibiase or Agalsidase or GLA or EC 3.2.1.22) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to Alpha Galactosidase A (Alpha D-Galactosidase A or Alpha D Galactoside Galactohydrolase or Melibiase or Agalsidase or GLA or EC 3.2.1.22) targeted therapeutics

Reasons to buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand the targeted therapy areas and indications for Alpha Galactosidase A (Alpha D-Galactosidase A or Alpha D Galactoside Galactohydrolase or Melibiase or Agalsidase or GLA or EC 3.2.1.22)
  • Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Alpha Galactosidase A (Alpha D-Galactosidase A or Alpha D Galactoside Galactohydrolase or Melibiase or Agalsidase or GLA or EC 3.2.1.22) development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Table of Contents
Product Code: GMDHC2070TDB

Table of Contents

List of Tables

List of Figures

  • Introduction
  • Global Markets Direct Report Coverage
  • Alpha Galactosidase A (Alpha D-Galactosidase A or Alpha D Galactoside Galactohydrolase or Melibiase or Agalsidase or GLA or EC 3.2.1.22) - Overview
  • Alpha Galactosidase A (Alpha D-Galactosidase A or Alpha D Galactoside Galactohydrolase or Melibiase or Agalsidase or GLA or EC 3.2.1.22) - Therapeutics Development
  • Products under Development by Stage of Development
  • Products under Development by Therapy Area
  • Products under Development by Indication
  • Products under Development by Companies
  • Products under Development by Universities/Institutes
  • Alpha Galactosidase A (Alpha D-Galactosidase A or Alpha D Galactoside Galactohydrolase or Melibiase or Agalsidase or GLA or EC 3.2.1.22) - Therapeutics Assessment
  • Assessment by Mechanism of Action
  • Assessment by Route of Administration
  • Assessment by Molecule Type
  • Alpha Galactosidase A (Alpha D-Galactosidase A or Alpha D Galactoside Galactohydrolase or Melibiase or Agalsidase or GLA or EC 3.2.1.22) - Companies Involved in Therapeutics Development
  • 4D Molecular Therapeutics Inc
  • Amicus Therapeutics Inc
  • AVROBIO Inc
  • Biosidus SA
  • Chiesi Farmaceutici SpA
  • Freeline Therapeutics Ltd
  • Greenovation Biotech GmbH
  • Moderna Therapeutics Inc
  • Pharming Group NV
  • Sangamo Therapeutics Inc
  • UniQure NV
  • Alpha Galactosidase A (Alpha D-Galactosidase A or Alpha D Galactoside Galactohydrolase or Melibiase or Agalsidase or GLA or EC 3.2.1.22) - Drug Profiles
  • 4D-310 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • agalsidase alfa - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • agalsidase beta biosimilar - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • AMT-190 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • AVRRD-01 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • FLT-190 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Gene Therapy to Activate GLA for Fabry Disease - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Gene Therapy to Activate GLA for Fabry Disease - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • migalastat hydrochloride - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • MOSS-AGAL - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • mRNA-3630 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • pegunigalsidase alfa - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • PGN-005 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • ST-920 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Alpha Galactosidase A (Alpha D-Galactosidase A or Alpha D Galactoside Galactohydrolase or Melibiase or Agalsidase or GLA or EC 3.2.1.22) - Dormant Products
  • Alpha Galactosidase A (Alpha D-Galactosidase A or Alpha D Galactoside Galactohydrolase or Melibiase or Agalsidase or GLA or EC 3.2.1.22) - Discontinued Products
  • Alpha Galactosidase A (Alpha D-Galactosidase A or Alpha D Galactoside Galactohydrolase or Melibiase or Agalsidase or GLA or EC 3.2.1.22) - Product Development Milestones
  • Featured News & Press Releases
  • Nov 27, 2019: Protalix BioTherapeutics hosting key opinion leader meeting on PRX-102 drug candidate for the treatment of Fabry Disease
  • Nov 18, 2019: Protalix BioTherapeutics and Chiesi Farmaceutici announce successful pre-BLA meeting with FDA for accelerated approval of pegunigalsidase alfa for the treatment of Fabry Disease in the United States
  • Oct 17, 2019: Protalix BioTherapeutics announces positive 12-month interim data from the BRIDGE phase III open label switch-over study of Pegunigalsidase Alfa for the treatment of Fabry Disease
  • Sep 25, 2019: Protalix and Chiesi close enrolment in Phase III Fabry disease trial
  • Sep 12, 2019: Freeline doses patient in first Fabry Disease AAV gene therapy trial globally
  • Aug 02, 2019: Amicus Therapeutics receives marketing authorization for galafold (migalastat) for fabry disease in Argentina
  • Jul 15, 2019: AVROBIO announces 87% substrate reduction in first kidney biopsy and additional positive data from clinical trials of AVR-RD-01 investigational gene therapy in Fabry Disease
  • Jul 02, 2019: Handok releases Fabry disease treatment
  • Jun 17, 2019: Protalix Biotherapeutics completes enrollment in the phase III bright clinical trial of Pegunigalsidase Alfa (PRX 102) for the treatment of Fabry disease
  • Jun 06, 2019: Protalix BioTherapeutics and Chiesi Farmaceutici to apply for accelerated approval of pegunigalsidase alfa for the treatment of Fabry Disease in the United States
  • May 30, 2019: 4D Molecular Therapeutics announces presentation of preclinical data at the 6th International Update on Fabry Disease and provides clinical update
  • May 28, 2019: Freeline presents preclinical data and phase 1/2 study design of the FLT190 AAV gene therapy for Fabry Disease
  • May 02, 2019: uniQure announces new preclinical data on fabry disease in oral presentations at the 22nd ASGCT Annual Meeting
  • May 01, 2019: Avrobio to incorporate plato platform into FAB-201 Phase II trial
  • Apr 15, 2019: uniQure to present data on Gene Therapy for Fabry Disease at ASGCT 2019
  • Appendix
  • Methodology
  • Coverage
  • Secondary Research
  • Primary Research
  • Expert Panel Validation
  • Contact Us
  • Disclaimer

List of Tables

  • Number of Products under Development by Stage of Development, H2 2019
  • Number of Products under Development by Therapy Areas, H2 2019
  • Number of Products under Development by Indication, H2 2019
  • Number of Products under Development by Companies, H2 2019
  • Products under Development by Companies, H2 2019
  • Number of Products under Investigation by Universities/Institutes, H2 2019
  • Products under Investigation by Universities/Institutes, H2 2019
  • Number of Products by Stage and Mechanism of Actions, H2 2019
  • Number of Products by Stage and Route of Administration, H2 2019
  • Number of Products by Stage and Molecule Type, H2 2019
  • Pipeline by 4D Molecular Therapeutics Inc, H2 2019
  • Pipeline by Amicus Therapeutics Inc, H2 2019
  • Pipeline by AVROBIO Inc, H2 2019
  • Pipeline by Biosidus SA, H2 2019
  • Pipeline by Chiesi Farmaceutici SpA, H2 2019
  • Pipeline by Freeline Therapeutics Ltd, H2 2019
  • Pipeline by Greenovation Biotech GmbH, H2 2019
  • Pipeline by Moderna Therapeutics Inc, H2 2019
  • Pipeline by Pharming Group NV, H2 2019
  • Pipeline by Sangamo Therapeutics Inc, H2 2019
  • Pipeline by UniQure NV, H2 2019
  • Dormant Projects, H2 2019
  • Discontinued Products, H2 2019

List of Figures

  • Number of Products under Development by Stage of Development, H2 2019
  • Number of Products by Mechanism of Actions, H2 2019
  • Number of Products by Stage and Mechanism of Actions, H2 2019
  • Number of Products by Routes of Administration, H2 2019
  • Number of Products by Stage and Routes of Administration, H2 2019
  • Number of Products by Molecule Types, H2 2019
  • Number of Products by Stage and Molecule Types, H2 2019
Back to Top